Shares of Kamada (NASDAQ:KMDA) were flat in pre-market trading after the company reported Q1 results.
Earnings per share were unchanged 0.00% year over year to $0.12, which beat the estimate of $0.06.
Revenue of $33,290,000 rose by 24.23% year over year, which beat the estimate of $30,120,000.
Kamada hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 18, 2020
Time: 08:30 AM
ET Webcast URL: https://www.kamada.com/events-presentations/
Recent Stock Performance
Company's 52-week high was at $8.00
Company's 52-week low was at $4.40
Price action over last quarter: Up 14.17%
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing and marketing of specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX etc. The company has Proprietary products and Distribution segments. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from Proprietary products segment and generates the majority of sales from the United States. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.